Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT
· Real-Time Price · USD
3.81
-0.12 (-3.05%)
At close: May 02, 2025, 3:59 PM
3.81
-0.15%
After-hours: May 02, 2025, 05:45 PM EDT
-3.05% (1D)
| Bid | 3.75 |
| Market Cap | 117.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.57M |
| EPS (ttm) | -1.45 |
| PE Ratio (ttm) | -2.63 |
| Forward PE | -0.78 |
| Analyst | Buy |
| Ask | 3.82 |
| Volume | 846,775 |
| Avg. Volume (20D) | 585,640 |
| Open | 3.98 |
| Previous Close | 3.93 |
| Day's Range | 3.78 - 4.12 |
| 52-Week Range | 1.73 - 7.38 |
| Beta | 2.36 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2023
Employees 14
Stock Exchange NASDAQ
Ticker Symbol SGMT
Website https://sagimet.com
Analyst Forecast
According to 6 analyst ratings, the average rating for SGMT stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 712.58% from the latest price.
Stock Forecasts3 months ago
+10%
Sagimet Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
5 months ago
-13.95%
Sagimet Biosciences shares are trading lower after the company reported worse-than-expected Q3 EPS results.
